Abstract
Recently, we identified ubiquinol‐cytochrome c reductase binding protein (UQCRB), one of subunits of mitochondrial Complex III, as a target protein of the anti‐angiogenic natural small molecule, terpestacin. The Complex III of mitochondrial respiratory chain has been considered as a key regulator in hypoxia‐induced angiogenesis through mitochondria‐derived reactive oxygen species (ROS) involved in O2 sensing. Here, cell permeable UQCRB protein is generated using protein transduction domain (PTD), a small peptide transferring its binding complex into the cell, to reveal the biological function of UQCRB. Consequently, intracellular delivery of PTD‐UQCRB fusion protein enhances generation of mitochondrial ROS and HIF‐1α stability. Also, PTD‐UQCRB transduction induces vascular endothelial growth factor (VEGF) expression and invasion of human umbilical vascular endothelial cells (HUVECs) in vitro. Furthermore, trans‐membrane delivery of PTD‐UQCRB enhances wound healing in vivo. These results provide new insights into the function of PTD‐UQCRB in angiogenesis via mitochondria mediated ROS generation and also open new basis on application of PTD‐UQCRB as a pro‐angiogenic agent via regulating mitochondrial function. This study is supported by self‐research funding.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.